FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068280585> ?p ?o ?g. }

• W2068280585 endingPage "241" @default.
• W2068280585 startingPage "232" @default.
• W2068280585 abstract "One of the key events in post-angioplasty restenosis is the migration and proliferation of medial smooth muscle cells leading to neo-intima formation. This phase is mediated by several growth factors, mainly platelet-derived growth factor (PDGF), basic fibroblast growth factor (FGF2/bFGF) and heparin-binding epidermal growth factor (HB-EGF). In this study, we have focused on the role of FGF2, which requires heparan sulfate proteoglycans (HSPG) as cofactors for binding and activation of its cell surface tyrosine kinase receptor. The aim of this study was to identify and explore the effect of novel FGF antagonists on vascular smooth muscle cell (VSMC) proliferation.We have recently identified a novel class of small, positively charged molecules sharing a porphyrin core as inhibitors of FGF2 and vascular endothelial growth factor (VEGF) activity. Here we investigated the inhibitory effect of these compounds on VSMC proliferation and their effect on heparin-induced FGF receptor activity.We found that these molecules exert a marked inhibitory effect on FGF2-mediated smooth muscle cell (SMC) proliferation, manifested by reduced cell growth and DNA synthesis, which occurred in a dose-dependent manner with an IC(50) of approximately 1 microM of inhibitor. We demonstrate that the molecule, 5, 10, 15, 20-tetrakis (methyl-4-pyridyl)-21H, 23H-porphine tetra-p-tosylate salt (TMPP), inhibits binding of radiolabeled FGF2 to SMCs and to soluble FGF receptor 1 (FGFR1) in a manner that interferes with both ligand and receptor interactions with heparin, thereby blocking growth factor mediated SMC proliferation.We have identified an FGF antagonist, which may serve in clinical practice as a preventive measure of restenosis." @default.
• W2068280585 created "2016-06-24" @default.
• W2068280585 creator A5014417696 @default.
• W2068280585 creator A5042082590 @default.
• W2068280585 creator A5057859390 @default.
• W2068280585 creator A5071162611 @default.
• W2068280585 creator A5080211133 @default.
• W2068280585 date "2002-01-01" @default.
• W2068280585 modified "2023-10-12" @default.
• W2068280585 title "Inhibition of vascular smooth muscle cell proliferation by a novel fibroblast growth factor receptor antagonist" @default.
• W2068280585 cites W129207505 @default.
• W2068280585 cites W1487884828 @default.
• W2068280585 cites W1771537070 @default.
• W2068280585 cites W1854803455 @default.
• W2068280585 cites W1969486006 @default.
• W2068280585 cites W1973553476 @default.
• W2068280585 cites W1974873948 @default.
• W2068280585 cites W1980286820 @default.
• W2068280585 cites W1981566905 @default.
• W2068280585 cites W1992787804 @default.
• W2068280585 cites W1995347825 @default.
• W2068280585 cites W2006641366 @default.
• W2068280585 cites W2009431859 @default.
• W2068280585 cites W2013012232 @default.
• W2068280585 cites W2021513166 @default.
• W2068280585 cites W2027189433 @default.
• W2068280585 cites W2030155901 @default.
• W2068280585 cites W2034487226 @default.
• W2068280585 cites W2041819693 @default.
• W2068280585 cites W2044563596 @default.
• W2068280585 cites W2050069100 @default.
• W2068280585 cites W2050256171 @default.
• W2068280585 cites W2057330499 @default.
• W2068280585 cites W2063277519 @default.
• W2068280585 cites W2080363456 @default.
• W2068280585 cites W2090412760 @default.
• W2068280585 cites W2135949891 @default.
• W2068280585 cites W2143651667 @default.
• W2068280585 cites W2144488618 @default.
• W2068280585 cites W2144789534 @default.
• W2068280585 cites W2151516954 @default.
• W2068280585 cites W2157756102 @default.
• W2068280585 cites W2167544720 @default.
• W2068280585 cites W2169147580 @default.
• W2068280585 cites W2229467589 @default.
• W2068280585 cites W2318616726 @default.
• W2068280585 cites W2409992890 @default.
• W2068280585 cites W3133924569 @default.
• W2068280585 doi "https://doi.org/10.1016/s0008-6363(01)00447-3" @default.
• W2068280585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11744033" @default.
• W2068280585 hasPublicationYear "2002" @default.
• W2068280585 type Work @default.
• W2068280585 sameAs 2068280585 @default.
• W2068280585 citedByCount "32" @default.
• W2068280585 countsByYear W20682805852012 @default.
• W2068280585 countsByYear W20682805852013 @default.
• W2068280585 countsByYear W20682805852014 @default.
• W2068280585 countsByYear W20682805852017 @default.
• W2068280585 countsByYear W20682805852018 @default.
• W2068280585 countsByYear W20682805852020 @default.
• W2068280585 countsByYear W20682805852023 @default.
• W2068280585 crossrefType "journal-article" @default.
• W2068280585 hasAuthorship W2068280585A5014417696 @default.
• W2068280585 hasAuthorship W2068280585A5042082590 @default.
• W2068280585 hasAuthorship W2068280585A5057859390 @default.
• W2068280585 hasAuthorship W2068280585A5071162611 @default.
• W2068280585 hasAuthorship W2068280585A5080211133 @default.
• W2068280585 hasBestOaLocation W20682805851 @default.
• W2068280585 hasConcept C126322002 @default.
• W2068280585 hasConcept C130287650 @default.
• W2068280585 hasConcept C134018914 @default.
• W2068280585 hasConcept C170493617 @default.
• W2068280585 hasConcept C180361614 @default.
• W2068280585 hasConcept C185592680 @default.
• W2068280585 hasConcept C26375932 @default.
• W2068280585 hasConcept C2775960820 @default.
• W2068280585 hasConcept C2776362946 @default.
• W2068280585 hasConcept C2777587049 @default.
• W2068280585 hasConcept C2779395532 @default.
• W2068280585 hasConcept C2992686903 @default.
• W2068280585 hasConcept C42362537 @default.
• W2068280585 hasConcept C49418065 @default.
• W2068280585 hasConcept C55493867 @default.
• W2068280585 hasConcept C62112901 @default.
• W2068280585 hasConcept C62478195 @default.
• W2068280585 hasConcept C71924100 @default.
• W2068280585 hasConcept C74373430 @default.
• W2068280585 hasConcept C86803240 @default.
• W2068280585 hasConcept C95444343 @default.
• W2068280585 hasConceptScore W2068280585C126322002 @default.
• W2068280585 hasConceptScore W2068280585C130287650 @default.
• W2068280585 hasConceptScore W2068280585C134018914 @default.
• W2068280585 hasConceptScore W2068280585C170493617 @default.
• W2068280585 hasConceptScore W2068280585C180361614 @default.
• W2068280585 hasConceptScore W2068280585C185592680 @default.
• W2068280585 hasConceptScore W2068280585C26375932 @default.
• W2068280585 hasConceptScore W2068280585C2775960820 @default.
• W2068280585 hasConceptScore W2068280585C2776362946 @default.

• next